News headlines about IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) have been trending somewhat negative recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. IntelliPharmaCeutics Intl earned a coverage optimism score of -0.03 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.4533049994798 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the headlines that may have effected Accern’s rankings:

Shares of IntelliPharmaCeutics Intl (NASDAQ IPCI) traded up $0.15 during midday trading on Friday, reaching $0.95. The company’s stock had a trading volume of 8,277,356 shares, compared to its average volume of 766,143. The company has a market cap of $33.12, a price-to-earnings ratio of -2.79 and a beta of 0.99. IntelliPharmaCeutics Intl has a fifty-two week low of $0.70 and a fifty-two week high of $3.12.

A number of brokerages have weighed in on IPCI. Zacks Investment Research lowered IntelliPharmaCeutics Intl from a “hold” rating to a “sell” rating in a research note on Wednesday. Mackie upgraded IntelliPharmaCeutics Intl to a “hold” rating and upped their target price for the stock from $1.00 to $3.10 in a research note on Tuesday, September 26th. Finally, HC Wainwright began coverage on IntelliPharmaCeutics Intl in a research note on Friday. They issued a “buy” rating and a $2.50 target price on the stock. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. IntelliPharmaCeutics Intl has a consensus rating of “Hold” and an average target price of $2.40.

TRADEMARK VIOLATION NOTICE: “IntelliPharmaCeutics Intl (IPCI) Receives Daily Media Impact Rating of -0.03” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://theolympiareport.com/2018/01/19/intellipharmaceutics-intl-ipci-receives-daily-media-impact-rating-of-0-03.html.

IntelliPharmaCeutics Intl Company Profile

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

Insider Buying and Selling by Quarter for IntelliPharmaCeutics Intl (NASDAQ:IPCI)

Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.